Related Experiment Videos
Diuretics for Preventing Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review and Meta-Analysis
Shin Kato1, Masato Koizumi2, Jun Nirei3
1Department of Pediatrics, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan, shinkato2@gmail.com.
Insights
Diuretics do not prevent bronchopulmonary dysplasia (BPD) in preterm infants, according to current evidence. More research is needed to confirm their role and safety in BPD prevention strategies.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Pharmacology
Background:
- Bronchopulmonary dysplasia (BPD) remains a significant challenge in preterm infant care.
- Previous randomized controlled trials (RCTs) have not established the efficacy of diuretics in preventing BPD.
- Recent observational studies suggest a potential role for diuretics, necessitating an updated synthesis of evidence.
Purpose of the Study:
- To evaluate the preventive effects of diuretics on bronchopulmonary dysplasia (BPD) in preterm infants.
- To assess the safety profile of diuretic use in this vulnerable population.
- To synthesize evidence from both randomized and non-randomized studies.
Main Methods:
- Comprehensive literature search of MEDLINE, Embase, Cochrane CENTRAL, and CINAHL up to June 2025.
- Inclusion of 40 studies (6 RCTs, 34 non-randomized studies) evaluating various diuretic classes, routes, doses, and durations.
- Risk of bias assessment using RoB 2 and ROBINS-I; certainty of evidence graded by GRADE; meta-analysis using random-effects models.
Main Results:
- RCTs did not demonstrate a preventive effect of diuretics on BPD, focusing mainly on short-term lung mechanics.
- Meta-analysis revealed no significant effects of diuretics on death or BPD (RR, 1.10; 95% CI, 0.77-1.59) or mortality (RR, 0.44; 95% CI, 0.19-1.04).
- Electrolyte abnormalities were not significantly increased (RR, 1.51; 95% CI, 0.81-2.83); however, non-randomized studies suggested potential BPD reduction, but with low to very low certainty of evidence.
Conclusions:
- Current evidence does not confirm that diuretics prevent bronchopulmonary dysplasia (BPD).
- The safety profile of diuretics appears favorable, but evidence quality is limited by small sample sizes and confounding factors.
- Larger, adequately powered RCTs are essential to definitively explore the role of diuretics in BPD prevention.
Introduction:
Randomized controlled trials (RCTs) have not demonstrated that diuretics prevent bronchopulmonary dysplasia (BPD), but recent observational studies warrant an updated synthesis. We evaluated the preventive effects and safety of diuretics in preterm infants at risk of developing BPD.
Methods:
MEDLINE, Embase, Cochrane CENTRAL, and CINAHL were searched through June 2025. We included randomized and non-randomized studies of various diuretic classes with different routes, dosing regimens, and treatment durations. The risk of bias was assessed using the RoB 2 and ROBINS-I and the certainty of evidence using GRADE. Random-effects models were used to calculate the risk ratios and 95% confidence intervals.
Results:
Forty studies, including six RCTs, were analyzed. Furosemide was the most frequently used diuretic. The RCTs predominantly focused on short-term changes in lung mechanics and did not demonstrate any preventive effect of diuretics on BPD. The meta-analysis showed no significant effects of diuretics on death or BPD (RR, 1.10; 95% CI, 0.77-1.59) or mortality (RR, 0.44; 95% CI, 0.19-1.04). Electrolyte abnormalities were not significantly increased (RR, 1.51; 95% CI, 0.81-2.83). Non-randomized studies have reported a potential reduction in BPD occurrence. However, the overall certainty of the evidence is low to very low due to the small sample sizes and confounding.
Conclusion:
The current evidence does not confirm that diuretics prevent BPD. Given the uncertainty of the current evidence and the favorable safety profiles, adequately powered RCTs are needed to explore the potential role of diuretics in BPD prevention.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Breathing
Inhaled Medications
Pulmonary Cycle: Exhalation
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...